Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 3/20 | 0.44 |
| ▸ | PRKACA | P17612 | 1/20 | 0.38 |
| ▸ | PRKACG | P22612 | 1/20 | 0.38 |
| ▸ | PRKACB | P22694 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20275827 | 0.84 | DRD2 (0.68) | DRD2DRD3HTR1AHTR2CPRKACA | |
| SCHEMBL2146850 | 0.84 | DRD2 (0.68) | DRD2DRD3HTR1AHTR2CPRKACA | |
| SCHEMBL22425357 | 0.84 | DRD2 (0.68) | DRD2DRD3HTR1AHTR2CPRKACA | |
| SCHEMBL31116731 | 0.82 | DRD2 (0.49) | DRD2DRD3HTR1ASLC6A3 | |
| SCHEMBL30374018 | 0.80 | TSHR (0.47) | DRD2DRD3HTR1A | |
| SCHEMBL31116767 | 0.78 | DRD2 (0.43) | DRD2DRD3HTR1A | |
| SCHEMBL31116769 | 0.77 | CCR1 (0.37) | DRD2DRD3SLC6A3 | |
| SCHEMBL31116780 | 0.77 | CCR1 (0.37) | DRD2DRD3SLC6A3 | |
| SCHEMBL1499496 | 0.73 | TSHR (0.54) | HTR2CMEN1KMT2AHTR2ASLC6A4 | |
| SCHEMBL7779276 | 0.73 | TSHR (0.54) | HTR2CMEN1KMT2AHTR2ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250051316-A1 | 2-(ARYL-2-YL) MORPHOLINE AND DEUTERATED DERIVATIVE THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2025-02-13 | — | — | US | disclosed |
| EP-4428128-A1 | 2-(ARYL-2-YL) MORPHOLINE AND DEUTERATED DERIVATIVE THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2024-09-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051316-A1 | 2-(ARYL-2-YL) MORPHOLINE AND DEUTERATED DERIVATIVE THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | TAAR1, TAAR5, AVPR2 | DRD2 171/4885DRD3 334/4885HTR1A 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.